This is a prospective, Phase 2, single center, open-label study in adult patients with presumed WHO grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate PET/MR prior to surgery.
68Ga-citrate PET/MR Imaging for the Evaluation of Glioma in Adults
You can join if…
Open to people ages 18–85
WHO grade 3 or 4 glioma planning to undergo surgery
Age >= 18 years
Karnofsky performance status of >= 60
Ability to understand a written informed consent document, and the willingness to sign it
Cohort A - 20 subjects
Positive for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy Cohort B - 20 subjects
Negative for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy
You CAN'T join if...
Contraindications to PET imaging (e.g. pregnant or breast-feeding woman)
Contraindications to MR imaging (e.g. pacemakers, metallic implants, etc.)
University of California, San Franciscoaccepting new patients San Francisco, California, 94107, United States